Delving into the Latest Updates on 上海迈泰君奥生物技术有限公司 with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

融合蛋白	1

排名前五的靶点	数量

PDL1 x TGF-β	1

关联

1

项与上海迈泰君奥生物技术有限公司相关的药物

WO2023045141

专利挖掘

靶点

PDL1 x TGF-β

作用机制-

在研机构

上海迈泰君奥生物技术有限公司

原研机构

上海迈泰君奥生物技术有限公司

在研适应症

肿瘤

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

100 项与上海迈泰君奥生物技术有限公司相关的临床结果

登录后查看更多信息

0 项与上海迈泰君奥生物技术有限公司相关的专利（医药）

登录后查看更多信息

1

项与上海迈泰君奥生物技术有限公司相关的文献（医药）

Shanghai Yiyao

Study on retest period of poloxamer 188

作者: Hu Xiaoyu ; Zhang Cunchao ; Ren Pengcheng

Objective: To study the effect of Poloxamer 188 after the retest period on its quality and cell culture.Methods: The determination of p H, endotoxin content and cell culture and the identification of Raman spectra to poloxamer 188 at 6, 24 and 36 mo after the retest period were performed to evaluate its effects on cell growth and recombinant protein expression as a medium component.Results: The p H, endotoxin content and Raman identification of poloxamer 188 within 36 mo after the retest period met the related standardsPoloxamer 188 within 24 mo after retest date showed no differences in cell growth and viability and the protein expression compared with one within retest date, however, those indicators were all decreased when poloxamer 188 stored for 36 mo after retest date was used.Conclusion: The retest period of poloxamer 188 is suggested to be 24 mo after retest date as a component for serum free medium.

100 项与上海迈泰君奥生物技术有限公司相关的药物交易

登录后查看更多信息

100 项与上海迈泰君奥生物技术有限公司相关的转化医学

登录后查看更多信息